DrugPatentWatch Database Preview
Drugs in Development Information for Sevirumab
» See Plans and Pricing
What is the drug development status for Sevirumab?
Sevirumab is an investigational drug.
There have been 4 clinical trials for Sevirumab.
The most recent clinical trial was a Phase 2 trial.
The most common disease conditions in clinical trials are HIV Infections, Cytomegalovirus Retinitis, and Retinitis. The leading clinical trial sponsors are National Institute of Allergy and Infectious Diseases (NIAID), Sandoz, and Facet Biotech.
Summary for Sevirumab
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 0 |
| WIPO Patent Applications | 0 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 2 (1969-12-31) |
| Vendors | 0 |
Recent Clinical Trials for Sevirumab
| Title | Sponsor | Phase |
|---|---|---|
| A Phase II/III Trial of Human Anti-CMV Monoclonal Antibody MSL 109 (MACRT) | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 2 |
| Comparison of Two Methods in the Treatment of Cytomegalovirus of the Eyes in Patients With AIDS | Facet Biotech | Phase 2 |
| Comparison of Two Methods in the Treatment of Cytomegalovirus of the Eyes in Patients With AIDS | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 2 |
Clinical Trial Summary for Sevirumab
Top disease conditions for Sevirumab
Top clinical trial sponsors for Sevirumab
US Patents for Sevirumab
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
